Literature DB >> 9179670

Immunohistochemical study of tumor-infiltrating lymphocytes before and after intravesical bacillus Calmette-Guérin treatment for superficial bladder cancer.

S Honda1, Y Sakamoto, M Fujime, R Kitagawa.   

Abstract

BACKGROUND: This study investigated changes in the phenotypic characteristics of tumor-infiltrating lymphocytes during intravesical bacillus Calmette-Guérin (BCG) treatment using an immunohistochemical technique.
METHODS: A total of 16 patients with superficial bladder cancer underwent intravesical BCG treatment for therapeutic purposes. Tissue specimens were obtained from these patients before and after BCG treatment by cold cup biopsies.
RESULTS: The numbers of CD3+ cells, CD4+ cells, CD8+ cells, and CD19+ cells significantly increased after treatment compared with numbers before treatment (P < 0.01). Although gamma/delta T cells were not observed before treatment, they appeared after treatment in 6 patients. In all these patients, the tumors disappeared or their size was reduced by more than 50%, and none of the tumors recurred. The induction of CD25+ cells after treatment was seen in 11 of the 16 patients.
CONCLUSION: gamma/delta T cells may play an important role in the immune response of the host to the tumor in intravesical BCG treatment (although this correlation was statistically insignificant.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9179670     DOI: 10.1111/j.1442-2042.1997.tb00143.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  8 in total

Review 1.  Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Authors:  Shona Hendry; Roberto Salgado; Thomas Gevaert; Prudence A Russell; Tom John; Bibhusal Thapa; Michael Christie; Koen van de Vijver; M V Estrada; Paula I Gonzalez-Ericsson; Melinda Sanders; Benjamin Solomon; Cinzia Solinas; Gert G G M Van den Eynden; Yves Allory; Matthias Preusser; Johannes Hainfellner; Giancarlo Pruneri; Andrea Vingiani; Sandra Demaria; Fraser Symmans; Paolo Nuciforo; Laura Comerma; E A Thompson; Sunil Lakhani; Seong-Rim Kim; Stuart Schnitt; Cecile Colpaert; Christos Sotiriou; Stefan J Scherer; Michail Ignatiadis; Sunil Badve; Robert H Pierce; Giuseppe Viale; Nicolas Sirtaine; Frederique Penault-Llorca; Tomohagu Sugie; Susan Fineberg; Soonmyung Paik; Ashok Srinivasan; Andrea Richardson; Yihong Wang; Ewa Chmielik; Jane Brock; Douglas B Johnson; Justin Balko; Stephan Wienert; Veerle Bossuyt; Stefan Michiels; Nils Ternes; Nicole Burchardi; Stephen J Luen; Peter Savas; Frederick Klauschen; Peter H Watson; Brad H Nelson; Carmen Criscitiello; Sandra O'Toole; Denis Larsimont; Roland de Wind; Giuseppe Curigliano; Fabrice André; Magali Lacroix-Triki; Mark van de Vijver; Federico Rojo; Giuseppe Floris; Shahinaz Bedri; Joseph Sparano; David Rimm; Torsten Nielsen; Zuzana Kos; Stephen Hewitt; Baljit Singh; Gelareh Farshid; Sibylle Loibl; Kimberly H Allison; Nadine Tung; Sylvia Adams; Karen Willard-Gallo; Hugo M Horlings; Leena Gandhi; Andre Moreira; Fred Hirsch; Maria V Dieci; Maria Urbanowicz; Iva Brcic; Konstanty Korski; Fabien Gaire; Hartmut Koeppen; Amy Lo; Jennifer Giltnane; Marlon C Rebelatto; Keith E Steele; Jiping Zha; Kenneth Emancipator; Jonathan W Juco; Carsten Denkert; Jorge Reis-Filho; Sherene Loi; Stephen B Fox
Journal:  Adv Anat Pathol       Date:  2017-11       Impact factor: 3.875

Review 2.  Immunotherapy in genitourinary malignancies.

Authors:  Max M Wattenberg; Lawrence Fong; Ravi A Madan; James L Gulley
Journal:  Curr Opin Urol       Date:  2016-11       Impact factor: 2.309

3.  Predictive biomarkers of bacillus calmette-guérin immunotherapy response in bladder cancer: where are we now?

Authors:  Luís Lima; Mário Dinis-Ribeiro; Adhemar Longatto-Filho; Lúcio Santos
Journal:  Adv Urol       Date:  2012-08-07

4.  Bacillus Calmette-Guerin (BCG) induces superior anti-tumour responses by Vδ2+ T cells compared with the aminobisphosphonate drug zoledronic acid.

Authors:  J Fenn; L A Ridgley; A White; C Sarfas; M Dennis; A Dalgleish; R Reljic; S Sharpe; M Bodman-Smith
Journal:  Clin Exp Immunol       Date:  2022-06-23       Impact factor: 5.732

5.  Do Orthotopic Ileal Diversions Induce Immunological Changes in Retained Urethral Tissue?

Authors:  Günter Niegisch; Christina Hulsbergen-van de Kaa; Martine Ploeg; Kees Hendricksen; J Alfred Witjes
Journal:  Bladder Cancer       Date:  2015-04-30

6.  Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer.

Authors:  Renate Pichler; Josef Fritz; Claudia Zavadil; Georg Schäfer; Zoran Culig; Andrea Brunner
Journal:  Oncotarget       Date:  2016-06-28

Review 7.  Gamma Delta T Cell Therapy for Cancer: It Is Good to be Local.

Authors:  C David Pauza; Mei-Ling Liou; Tyler Lahusen; Lingzhi Xiao; Rena G Lapidus; Cristiana Cairo; Haishan Li
Journal:  Front Immunol       Date:  2018-06-08       Impact factor: 7.561

8.  Cohort profile: King's Health Partners bladder cancer biobank.

Authors:  Pinky Kotecha; Charlotte L Moss; Deborah Enting; Cheryl Gillett; Magdalene Joseph; Debra Josephs; Sarah Rudman; Simon Hughes; Fidelma Cahill; Harriet Wylie; Anna Haire; James Rosekilly; Muhammad Shamin Khan; Rajesh Nair; Ramesh Thurairaja; Sachin Malde; Mieke Van Hemelrijck
Journal:  BMC Cancer       Date:  2020-09-25       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.